BLOG

Bill Gates among investors as Cambridge Science Park-based Cerevance raises $45m to fight brain diseases

Bill Gates and GV have joined in a $45million Series B funding round for Cerevance, the pharmaceutical company with a Cambridge Science Park base. The company said it will use the money to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s.